INTRODUCTION: Intravitreal antivascular endothelial growth factor (VEGF) drugs 
represent the first-line treatment option for wet age-related macular 
degeneration (w-AMD) and diabetic macular edema (DME); however, the frequent 
injection intervals have illuminated to the necessity for new molecules allowing 
a more prolonged treatment regimen. Faricimab is a promising bispecific drug 
targeting VEGF-A and the Ang-Tie/pathway. Phase II STAIRWAY and AVENUE Trials 
showed its clinical efficacy for the treatment of w-AMD, while the phase II 
BOULEVARD Trial revealed its superiority to monthly ranibizumab in the 
management of DME with a monthly treatment regimen. The agents are awaiting 
approval for the treatment of w-AMD and DME.
AREAS COVERED: This article presents an overview of w-AMD and diabetic 
retinopathy and examines the progress of Faricimab through clinical trials. It 
offers insights on where Faricimab may be placed in the future market of 
anti-VEGF treatments and discusses the role of Ang/Tie pathway as a potential 
additive weapon for the treatment of w-AMD, DME, and retinal vein occlusion 
(RVO).
EXPERT OPINION: The possibility of administering faricimab with more prolonged 
treatment intervals represents an important advantage to decrease the treatment 
burden and improve patient compliance. Further phase III trials should provide 
more evidence on clinical efficacy.